Vanguard Group Inc. Purchases 1,088,912 Shares of Geron Co. (NASDAQ:GERN)

Vanguard Group Inc. lifted its position in Geron Co. (NASDAQ:GERN - Free Report) by 3.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 33,538,822 shares of the biopharmaceutical company's stock after buying an additional 1,088,912 shares during the quarter. Vanguard Group Inc. owned about 5.55% of Geron worth $118,727,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also modified their holdings of the company. State Street Corp boosted its stake in Geron by 28.4% during the 3rd quarter. State Street Corp now owns 28,961,671 shares of the biopharmaceutical company's stock valued at $131,486,000 after purchasing an additional 6,413,204 shares during the period. Geode Capital Management LLC raised its stake in Geron by 1.8% during the 3rd quarter. Geode Capital Management LLC now owns 13,067,999 shares of the biopharmaceutical company's stock valued at $59,339,000 after purchasing an additional 231,178 shares during the last quarter. Wellington Management Group LLP boosted its holdings in Geron by 4.7% in the 3rd quarter. Wellington Management Group LLP now owns 12,662,404 shares of the biopharmaceutical company's stock valued at $57,487,000 after purchasing an additional 570,580 shares during the period. Charles Schwab Investment Management Inc. grew its position in Geron by 1.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 4,523,864 shares of the biopharmaceutical company's stock worth $16,014,000 after purchasing an additional 73,482 shares during the last quarter. Finally, abrdn plc increased its holdings in shares of Geron by 24.2% during the 4th quarter. abrdn plc now owns 1,847,285 shares of the biopharmaceutical company's stock worth $6,539,000 after purchasing an additional 360,027 shares during the period. 73.71% of the stock is owned by institutional investors.

Geron Trading Up 6.2 %

NASDAQ:GERN traded up $0.08 during mid-day trading on Friday, hitting $1.38. The company had a trading volume of 9,210,997 shares, compared to its average volume of 11,414,116. The firm has a market cap of $878.93 million, a P/E ratio of -4.31 and a beta of 0.66. Geron Co. has a fifty-two week low of $1.19 and a fifty-two week high of $5.34. The business's fifty day moving average is $1.93 and its two-hundred day moving average is $3.12. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.74 and a current ratio of 2.89.

Geron (NASDAQ:GERN - Get Free Report) last announced its quarterly earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.04). The business had revenue of $47.54 million for the quarter, compared to the consensus estimate of $45.29 million. Geron had a negative net margin of 682.48% and a negative return on equity of 67.53%. As a group, research analysts expect that Geron Co. will post -0.25 earnings per share for the current year.

Analyst Upgrades and Downgrades

GERN has been the topic of a number of recent research reports. Barclays reissued an "overweight" rating and set a $4.00 target price (down from $9.00) on shares of Geron in a research report on Thursday, February 27th. HC Wainwright restated a "neutral" rating on shares of Geron in a research report on Wednesday, March 12th. Scotiabank dropped their target price on Geron from $6.00 to $4.00 and set a "sector outperform" rating for the company in a report on Thursday, February 27th. B. Riley lowered Geron from a "buy" rating to a "neutral" rating and decreased their price target for the company from $3.50 to $2.00 in a research note on Thursday, February 27th. Finally, Stifel Nicolaus dropped their price objective on Geron from $8.00 to $4.00 and set a "buy" rating for the company in a research note on Thursday, February 27th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Geron currently has a consensus rating of "Moderate Buy" and an average target price of $5.75.

Geron Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.